Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. (8th October 2019)

• Record Type: Journal Article
• Authors: Ryerson, Lana Zhovtis; Foley, John; Chang, Ih; Kister, Ilya; Cutter, Gary; Metzger, Ryan R.; Goldberg, Judith D.; Li, Xiaochun; Riddle, Evan; Smirnakis, Karen; Kasliwal, Rachna; Ren, Zheng; Hotermans, Christophe; Ho, Pei-Ran; Campbell, Nolan
• Is Part Of: Neurology. Volume 93:Number 15(2019)
• Publication Date: 2019-10-08
• Subjects: Neurology -- Periodicals; Neurology -- Periodicals; Neurologie -- Périodiques; 616.8
• DOI: 10.1212/WNL.0000000000008243
• Languages: English
• ISSNs: 0028-3878

Abstract

Abstract : Objective: To use the large dataset from the Tysabri Outreach: Unified Commitment to Health (TOUCH) program to compare progressive multifocal leukoencephalopathy (PML) risk with natalizumab extended interval dosing (EID) vs standard interval dosing (SID) in patients with multiple sclerosis (MS). Methods: This retrospective cohort study included anti-JC virus antibody-positive patients (n = 35, 521) in the TOUCH database as of June 1, 2017. The effect of EID on PML risk was evaluated with 3 planned analyses using Kaplan-Meier methods stratified by prior immunosuppressant use. Risk of PML was analyzed by Cox regression adjusted for age, sex, prior immunosuppressants, time since natalizumab initiation, and cumulative number of infusions. Results: This study included 35, 521 patients (primary analysis: 1, 988 EID, 13, 132 SID; secondary analysis: 3, 331 EID, 15, 424 SID; tertiary analysis: 815 EID, 23, 168 SID). Mean average dosing intervals were 35.0 to 43.0 and 29.8 to 30.5 days for the EID and SID cohorts, respectively. Hazard ratios (95% confidence intervals) of PML risk for EID vs SID were 0.06 (0.01–0.22, p < 0.001) and 0.12 (0.05–0.29, p < 0.001) for the primary and secondary analyses, respectively. Relative risk reductions were 94% and 88% in favor of EID for the primary and secondary analyses, respectively. The tertiary analysis included no cases of PML with EID. Conclusion: Natalizumab EID is associated with clinically and statistically significantly lower PML risk than SID. Classification of evidence: This study provides Class III evidence that for patients with MS, natalizumab EID is associated with a lower PML risk than SID.